Carregant...
An updated review of the treatment landscape for advanced gastrointestinal stromal tumors
Before the introduction of tyrosine kinase inhibitors (TKIs), the overall survival of patients with advanced or metastatic gastrointestinal stromal tumors (GISTs) was 10 to 20 months because of the lack of approved therapies. In the last 20 years, a treatment algorithm for patients with advanced GIS...
Guardat en:
| Publicat a: | Cancer |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8252111/ https://ncbi.nlm.nih.gov/pubmed/33974733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33630 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|